Article Details
Retrieved on: 2025-04-25 14:07:35
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the Phase 2 BEHOLD study of the senolytic UBX1325 for diabetic macular edema, highlighting its efficacy in improving vision by targeting senescent cells, relating to diabetes through complications like diabetic retinopathy.
Article found on: www.ophthalmologytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here